247 related articles for article (PubMed ID: 25250560)
21. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Agell L; Hernández S; Salido M; de Muga S; Juanpere N; Arumí-Uria M; Menendez S; Lorenzo M; Lorente JA; Serrano S; Lloreta J
Mod Pathol; 2011 Mar; 24(3):443-52. PubMed ID: 21113138
[TBL] [Abstract][Full Text] [Related]
22. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
Zhu K; Yan H; Wang R; Zhu H; Meng X; Xu X; Dou X; Chen D
Med Oncol; 2014 Jul; 31(7):16. PubMed ID: 24861917
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis and clinical correlation of metastatic colorectal cancer.
Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
[TBL] [Abstract][Full Text] [Related]
24. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.
Shanmugam V; Ramanathan RK; Lavender NA; Sinari S; Chadha M; Liang WS; Kurdoglu A; Izatt T; Christoforides A; Benson H; Phillips L; Baker A; Murray C; Hostetter G; Von Hoff DD; Craig DW; Carpten JD
BMC Med Genomics; 2014 Jun; 7():36. PubMed ID: 24943349
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population.
Qiu Y; Fu X; Zhang W; Xu Y; Xiao L; Chen X; Shi L; Zhou X; Xia G; Peng Y; Deng M
J Clin Pathol; 2014 Jun; 67(6):491-8. PubMed ID: 24570042
[TBL] [Abstract][Full Text] [Related]
26. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
27. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
[TBL] [Abstract][Full Text] [Related]
28. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Simi L; Pratesi N; Vignoli M; Sestini R; Cianchi F; Valanzano R; Nobili S; Mini E; Pazzagli M; Orlando C
Am J Clin Pathol; 2008 Aug; 130(2):247-53. PubMed ID: 18628094
[TBL] [Abstract][Full Text] [Related]
29. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
30. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
31. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
32. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
Herreros-Villanueva M; Gomez-Manero N; Muñiz P; García-Girón C; Coma del Corral MJ
Mol Biol Rep; 2011 Feb; 38(2):1347-51. PubMed ID: 20571907
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
[TBL] [Abstract][Full Text] [Related]
36. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.
Sylvester BE; Huo D; Khramtsov A; Zhang J; Smalling RV; Olugbile S; Polite BN; Olopade OI
Clin Cancer Res; 2012 Jan; 18(2):350-9. PubMed ID: 22114137
[TBL] [Abstract][Full Text] [Related]
38. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
39. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
Balschun K; Haag J; Wenke AK; von Schönfels W; Schwarz NT; Röcken C
J Mol Diagn; 2011 Jul; 13(4):436-45. PubMed ID: 21704278
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]